Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

BASF Will Manufacture Astaxanthin for Cardax

  • BASF will exclusively manufacture a specialized form of astaxanthin, a key intermediate used to make Cardax Pharmaceuticals’ lead compound, Xancor™, for cardiovascular inflammatory disease.

    BASF will produce this material in sufficient quantity for preclinical, clinical, and eventually commercial use, according to the joint development and supply agreement between the two companies.

    As part of the agreement, Cardax has granted BASF an option for a royalty-bearing license for nutraceutical use of the specialized form of astaxanthin. All pharmaceutical applications of Xancor will remain the property of Cardax.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »